Gloria Ying (06821) plans to increase capital by 1.05 billion yuan in Shanghai Gloria Ying biotechnology development

Zhitongcaijing · 1d ago

According to Zhitong Finance App News, Gloria Wing (06821) announced that on July 30, 2026, the company and target companies Shanghai Gloria Ying Biotechnology Development Co., Ltd., Gloria Biotech, Gao Lin Qi Rui, Zhuhai Daiheng, Dr. Hao Hong, Gloria Tongxin and Haihe Gloria Ying Fund signed a capital increase agreement. Based on this, the company and investors agreed to increase the target company's share capital, totaling RMB 1,237 million. The company, Dr. Gao Yu Qirui, and Dr. Hao Hong will invest 1.05 billion yuan, 177 million yuan and 12.7 million yuan respectively.

By entering into a capital increase agreement, the target company will be able to introduce external investment through capital increase and share expansion, which is in line with the Group's future development strategy. This capital increase is conducive to enhancing the financial strength of the target company, meeting the capital requirements of the target company's subsequent capital expenditure and operating expenses, enhancing the target company's overall competitiveness and promoting the development of the target company's CDMO business (including macromolecular drugs, antibody-conjugated drugs, mRNA drugs and other advanced therapies).

As of the date of this announcement, the target company is a non-wholly-owned subsidiary of the Company (the Company holds approximately 83.00% interest). The target company operates the group's contract R&D and manufacturing service (CDMO) business for macromolecular drugs, antibody drug conjugates, mRNA and other advanced therapeutics. After the capital increase is completed, the target company will own approximately 83.50% of the company's equity and will remain a non-wholly-owned subsidiary of the company.